News Formal

Eli Lilly reports earnings Thursday. Here's what Wall Street is watching

  • 📰 CNBC
  • ⏱ Reading Time:
  • 21 sec. here
  • 10 min. at publisher
  • 📊 Quality Score:
  • News: 40%
  • Publisher: 72%

Amgen Inc News

Eli Lilly And Co,Novo Nordisk A/S,Breaking News: Investing

Novo Nordisk saw price pressure for its GLP-1 drugs Ozempic and Wegovy. Investors want to know how Eli Lilly's Zepbound performed.

Investors want to know whether Eli Lilly is seeing the same pricing pressures on its blockbuster weight loss drug Zepbound that Novo Nordisk experienced with its competing drug Wegovy in the second quarter. Novo Nordisk shocked investors on Wednesday when its latest results fell short of Wall Street's expectations. Shares are reeling, down 8%, after the company lowered its forecast for 2024 operating profit growth.

Barclays analyst Emily Field told clients in a research note that she would be a buyer of Novo Nordisk shares on the weakness. "Was this the picture perfect quarter we'd hoped for? Not necessarily," she said. "But at the end of the day, obesity is going to be a volume driven market and the overwhelming message we got from the company this morning is that volume is on track.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in ZA

South Africa South Africa Latest News, South Africa South Africa Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

10 things to watch in the stock market Friday, including tech rotation and Eli Lilly approvalThe S&P 500 and Nasdaq Composite were little unchanged in premarket trading as tech stocks look to stabilize after a rotation from 2024 winners.
Source: CNBC - 🏆 12. / 72 Read more »